Spontaneous bacterial peritonitis: Prevention and therapy
1990; Lippincott Williams & Wilkins; Volume: 12; Issue: 4 Linguagem: Inglês
10.1002/hep.1840120424
ISSN1527-3350
Autores Tópico(s)Amoebic Infections and Treatments
ResumoHepatologyVolume 12, Issue 4 p. 776-781 EditorialFree Access Spontaneous bacterial peritonitis: Prevention and therapy John Carl Hoefs M.D., Corresponding Author John Carl Hoefs M.D. Department of Medicine, University of California Irvine Medical Center, Irvine, California 92707Director of Liver Disease Program, University of California Irvine Medical Center, 101 City Drive South, Orange, CA 92668===Search for more papers by this author John Carl Hoefs M.D., Corresponding Author John Carl Hoefs M.D. Department of Medicine, University of California Irvine Medical Center, Irvine, California 92707Director of Liver Disease Program, University of California Irvine Medical Center, 101 City Drive South, Orange, CA 92668===Search for more papers by this author First published: October 1990 https://doi.org/10.1002/hep.1840120424Citations: 28AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon 1985; 31: 1–48. 10.1016/0011-5029(85)90002-1 PubMedWeb of Science®Google Scholar 2 Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodés J. Reticuloendothelial system phagocytic activity in cirrhosis and its relationship to bacterial infections and prognosis. Hepatology 1984; 4: 53–58. 10.1002/hep.1840040109 PubMedWeb of Science®Google Scholar 3 Wyke RJ. Problems of bacterial infection in patients with liver disease. Gut 1987; 28: 623–641. 10.1136/gut.28.5.623 CASPubMedWeb of Science®Google Scholar 4 Barnes PF, Arevalo C, Chan L, Wong S, Reynolds T. Prospective evaluation of bacteremic patients with chronic liver disease. Hepatology 1988; 8: 1099–1103. 10.1002/hep.1840080520 PubMedWeb of Science®Google Scholar 5 Cabrera J, Arroyo V, Ballestra AM, Rimola A, Gual J, Elena M, Rodés J. Aminoglycoside nephrotoxicity in cirrhosis: value of urinary B2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982; 82: 97–105. CASPubMedWeb of Science®Google Scholar 6 Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Ginés P, Rodes J. Cefotaxime is more effective than is ampicillintobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 457–462. 10.1002/hep.1840050319 PubMedWeb of Science®Google Scholar 7 Hoefs JC. Diagnostic paracentesis: a potent diagnostic tool. Gastroenterology 1990; 98: 230–236. 10.1016/0016-5085(90)91317-Y CASPubMedWeb of Science®Google Scholar 8 Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988; 8: 171–175. 10.1002/hep.1840080131 PubMedWeb of Science®Google Scholar 9 Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind placebocontrolled trial. Hepatology 1990; 12: 716–724. 10.1002/hep.1840120416 PubMedWeb of Science®Google Scholar 10 Donaldson RM. Normal bacterial populations of the intestine and their relation to intestinal function. N Engl J Med 1964; 270: 994–1001. 10.1056/NEJM196405072701907 PubMedWeb of Science®Google Scholar 11 Gorbach SL, Nahas L, Lerner PI, Weinstein L. Studies of intestinal microflora. Gastroenterology 1967; 53: 845–855. PubMedWeb of Science®Google Scholar 12 Mackowiak PA. The normal microbial flora. N Engl J Med 1982; 307: 83–93. 10.1056/NEJM198207083070203 CASPubMedWeb of Science®Google Scholar 13 Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95: 1351–1355. 10.1016/0016-5085(88)90372-1 CASPubMedWeb of Science®Google Scholar 14 Pinzello G, Simonetti R, Craxi A. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983; 3: 545–549. CASPubMedWeb of Science®Google Scholar 15 Albillos A, Cuervas-Mons V, Millan I, Canton T, Montes J, Barrios C, Garrido A, et al. Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. Gastroenterology 1990; 98: 134–140. 10.1016/0016-5085(90)91301-L CASPubMedWeb of Science®Google Scholar 16 Attali P, Turner K, Pelletier G. pH of ascitic fluid: diagnostic and prognostic value in cirrhotic and noncirrhotic patient. Gastroenterology 1986; 90: 1255–1265. 10.1016/0016-5085(86)90393-8 PubMedWeb of Science®Google Scholar 17 Tito L, Rimola A, Ginés P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27–31. 10.1002/hep.1840080107 PubMedWeb of Science®Google Scholar 18 Hoefs JC, Canawati HN, Sapico FL, Hopkins RR, Weiner J, Montgomerie JZ. Spontaneous bacterial peritonitis. Hepatology 1982; 2: 399–407. 10.1002/hep.1840020402 CASPubMedWeb of Science®Google Scholar 19 Xiol X, Castellote J, Baliellas C, Ariza J, Roca AG, Guardiola J, Casais L. Spontaneous bacterial empyema in cirrhotic patients: analysis of eleven cases. Hepatology 1990; 11: 365–370. 10.1002/hep.1840110306 PubMedWeb of Science®Google Scholar 20 Floch MH, Katz J, Conn HO. Qualitative and quantitative relationships of the fecal flora in cirrhotic patients with portal systemic encephalopathy and following portacaval anastomosis. Gastroenterology 1970; 59: 70–74. 10.1016/S0016-5085(19)33805-3 CASPubMedWeb of Science®Google Scholar 21 Dheeraj L, Gorbach SL, Levitan R. Intestinal microflora in patients with alcoholic cirrhosis: urea-splitting bacteria and neomycin resistance. Gastroenterology 1972; 62: 275–279. PubMedGoogle Scholar 22 Martini GA, Phear EA, Ruebener E, Sherlock S. The bacterial content of the small intestine in normal and cirrhotic subjects: relation to methionine toxicity. Clin Sci 1956; 16: 35–51. Web of Science®Google Scholar 23 Cerlek S, Mustrovic F, Govorcin B. Bacteriological analyses of the digestive tract in biliary cirrhosis before and after the administration of antibiotics. Med Pregl 1965; 18: 247–253. CASPubMedGoogle Scholar 24 Conn HO, Floch MH. Effects of lactulose and Lactobacillus acidophilus on the fecal flora. Am J Clin Nutr 1970; 23: 1588–1594. PubMedWeb of Science®Google Scholar 25 Spaulding EH, Tyson RR, Harris MJ, Jacobs B, Wildrick L, Johnson KO. Further studies on intestinal antiseptics: neomycin, nystatin. In: H Welch, F Marti-Ibanez, eds. Antibiotic Annual. New York: Medical Encyclopedia, Inc., 1956: 236–243. Google Scholar 26 Shidlovsky BA, Marmell M, Turell R, Prigot A. Studies on bowel sterilization with neomycin in combination with chemotherapeutic agent, kaprylex. In: H Welch, F Marti-Ibanez, eds. Antibiotic Annual. New York: Medical Encyclopedia, Inc., 1955: 98–101. Google Scholar 27 Dearing WH, Needham GM. Effects of oral use of neomycin plus bacitracin on intestinal flora of man. Proc Mayo Clin 1957; 34: 127–131. PubMedWeb of Science®Google Scholar 28 Weinstein L, Samet CA, Meade RH. Effect of paromomycin on the bacterial flora of the human intestine. JAMA 1961; 178: 891–897. 10.1001/jama.1961.03040480021005 CASPubMedWeb of Science®Google Scholar 29 Emmelot CH, van der Waaij D. The dose at which neomycin and polymyxin B can be applied for selective decontamination of the digestive tract. J Hyg 1980; 84: 331–340. 10.1017/S0022172400026851 CASPubMedWeb of Science®Google Scholar 30 Guiot HFL, van Furth R. Partial antibiotic decontamination. Br Med J 1977; 1: 800–802. 10.1136/bmj.1.6064.798-a CASPubMedWeb of Science®Google Scholar 31 Fox RA, Dudley FS, Sherlock S. The serum concentrations of the third component of complement in liver disease. Gut 1971; 12: 574–578. 10.1136/gut.12.7.574 CASPubMedWeb of Science®Google Scholar 32 Kourilsky O, LeRoy C, Peltier AP. Complement and liver cell function in 53 patients with liver disease. Am J Med 1973; 55: 783–790. 10.1016/0002-9343(73)90259-3 CASPubMedWeb of Science®Google Scholar 33 Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing, and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986; 6: 252–262. 10.1002/hep.1840060217 CASPubMedWeb of Science®Google Scholar 34 Rabinovitz M, Gavaler JS, Kumar S, Kajani M, Van Thiel DH. Role of serum complement, immunoglobulins, and cell-mediated immune system in the pathogenesis of spontaneous bacterial peritonitis (SBP). Dig Dis Sci 1989; 34: 1547–1552. 10.1007/BF01537108 PubMedWeb of Science®Google Scholar 35 Snyder N, Atterbury CE, Correia JP, Conn HO. Increased concurrence of cirrhosis and bacterial endocarditis: a clinical and postmortem study. Gastroenterology 1977; 73: 1107–1113. CASPubMedWeb of Science®Google Scholar 36 Burroughs AK, Rosenstein IJ, Epstein O. Bacteriuria and primary biliary cirrhosis. Gut 1984; 25: 133–137. 10.1136/gut.25.2.133 CASPubMedWeb of Science®Google Scholar 37 Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon 1985; 31: 1–48. 10.1016/0011-5029(85)90002-1 PubMedWeb of Science®Google Scholar 38 Runyon BA. Low-protein concentration ascitic fluid predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 1343–1346. 10.1016/0016-5085(86)90185-X PubMedWeb of Science®Google Scholar 39 Runyon BA, Morrissey RL, Hoefs JC, Wyle FA. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 1985; 5: 634–637. 10.1002/hep.1840050419 CASPubMedWeb of Science®Google Scholar 40 Runyon BA. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 1988; 8 (3): 632–635. 10.1002/hep.1840080332 PubMedWeb of Science®Google Scholar 41 Such J, Guarner C, Enriquez J, Rodriguez JL, Seres I, Vilardell F. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988; 6: 80–84. 10.1016/S0168-8278(88)80465-3 PubMedWeb of Science®Google Scholar 42 Jonas G, Hoefs JC, Leach S, Thrupp L. Liver spleen scan reticuloendothelial shift (RES) of sulfur colloid predicts development of spontaneous bacterial peritonitis [Abstract]. Hepatology 1988; 8: 1351. Web of Science®Google Scholar 43 Hoefs JC. Increase in ascites white blood cell and protein concentrations during diuresis in patients with chronic liver disease. Hepatology 1981; 1: 249–254. 10.1002/hep.1840010310 PubMedWeb of Science®Google Scholar 44 Hoefs JC. The mechanism of ascitic fluid protein concentration increase during diuresis in patients with chronic liver disease. Am J Gastroenterol 1981; 76: 423–431. CASPubMedWeb of Science®Google Scholar 45 Hoefs JC. Determinants of ascitic fluid protein in cirrhosis [Abstract]. Clin Res 1978; 26: 151. Google Scholar 46 Dykes PW. A study of the effects of albumin infusion in patients with cirrhosis of the liver. Q J Med 1961; 30: 297–327. CASPubMedWeb of Science®Google Scholar 47 Patek Jr. AJ, Mankin H, Colcher H, Lowell A, Earle Jr. DP. The effects of intravenous injection of concentrated human serum albumin upon blood plasma, ascites and renal functions in three patients with cirrhosis of the liver. J Clin Invest 1948; 27: 135–144. 10.1172/JCI101916 CASPubMedWeb of Science®Google Scholar 48 Runyon BA, Antillon MR, Montano AA. Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement. Gastroenterology 1989; 97: 158–162. 10.1016/0016-5085(89)91430-3 CASPubMedWeb of Science®Google Scholar 49 Gerding DN, Hall WH, Schierl EA. Antibiotic concentrations in ascitic fluid of patients with ascites and bacterial peritonitis. Ann Intern Med 1977; 86: 708–713. 10.7326/0003-4819-86-6-708 PubMedWeb of Science®Google Scholar 50 Gerding DN, Kromhout JP, Sullivan JJ, Hall WH. Antibiotic penetrance of ascitic fluid in dogs. Antimicrob Agents Chemother 1976; 10: 850–855. 10.1128/AAC.10.5.850 CASPubMedWeb of Science®Google Scholar 51 Bodey GP, Rodriguez V. Infections in cancer patients on a protected environmental antibiotic program. Am J Med 1975; 59: 497–504. 10.1016/0002-9343(75)90257-0 CASPubMedWeb of Science®Google Scholar 52 Krick JA, Remington JS. Opportunistic invasive fungal infections in patients with leukemia and lymphoma. Clin Haematol 1976; 5: 249–310. PubMedWeb of Science®Google Scholar 53 Levine AS, Siegel SE, Schreiber AD, Hauser J, Goldstein IM, Seidler F, Simon R, et al. Protected environments and prophylactic antibiotics: a prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 1973; 288: 477–483. 10.1056/NEJM197303082881001 CASPubMedWeb of Science®Google Scholar 54 Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77: 707–714. 10.7326/0003-4819-77-5-707 PubMedWeb of Science®Google Scholar 55 van der Waaij D, Tielemans-Speltie TM, Roeck-Houben AMJ. Infection by and distribution of biotypes of enterobacteriaceae species in leukaemic patients treated under ward conditions and in units for protected isolation in seven hospitals in Europe. Infection 1977; 3: 188–194. 10.1007/BF01639756 Google Scholar 56 van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother 1982; 10: 263–270. 10.1093/jac/10.4.263 PubMedWeb of Science®Google Scholar 57 Wilson JM, Guiney DG. Failure of oral trimethoprimsulfamethoxazole prophylaxis in acute leukemia. N Engl J Med 1982; 306: 14–20. 10.1056/NEJM198201073060105 PubMedWeb of Science®Google Scholar 58 Weiser B, Lange M, Fialk MA, Singer C, Szatrowski TH, Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial. Ann Intern Med 1981; 95: 436–438. 10.7326/0003-4819-95-4-436 CASPubMedWeb of Science®Google Scholar 59 Kauffman CA, Liepman MK, Bergman AG, Mioduszewki J. Triethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Am J Med 1983; 74: 599–670. 10.1016/0002-9343(83)91017-3 CASPubMedWeb of Science®Google Scholar 60 Gualtieri RJ, Donowitz GR, Kaiser DL, Hess CE, Sande MA. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983; 74: 934–940. 10.1016/0002-9343(83)90785-4 CASPubMedWeb of Science®Google Scholar 61 Sen P, Kapila R, Chmel H, Armstrong DA, Louria DB. Superinfection: another look. Am J Med 1982; 73: 706–718. 10.1016/0002-9343(82)90414-4 CASPubMedWeb of Science®Google Scholar 62 Wade JC, Schimpff SC, Hargadon MT, Fortner CL, Young VM, Wiernik PH. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 1981; 304: 1057–1062. 10.1056/NEJM198104303041801 CASPubMedWeb of Science®Google Scholar 63 Schimpff SC. Infection prevention during granulocytopenia. In: JS Remington, MN Swartz. Current clinical topics in infectious diseases. New York: McGraw-Hill, 1980: 85–105. Google Scholar 64 de Jongh CA, Schimpff SC, Wiernik PH. Antibiotic prophylaxis in acute leukemia. Ann Intern Med 1981; 95: 783–784. 10.7326/0003-4819-95-6-783_3 CASPubMedWeb of Science®Google Scholar 65 Gurwith MJ, Brunton JL, Lank BA, Harding GKM, Ronald AR. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979; 66: 248–256. 10.1016/0002-9343(79)90539-4 CASPubMedWeb of Science®Google Scholar 66 Sleijfer DTH, Mulder NH, de Vries-Hospers HG, Fidler V, Nieweg HO, van der Waaij D, van Saenes HKF. Infection prevention in granulocytopenic patients by selective decontamination of digestive tract. Eur J Cancer 1980; 16: 859–869. 10.1016/0014-2964(80)90140-1 CASPubMedWeb of Science®Google Scholar 67 de Vries-Hospers HG, Sleijfer DT, Mulder NH, van der Waaij D, Nieweg HO, van Saene HKF. Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. Antimicrob Agents Chemother 1981; 19: 813–820. 10.1128/AAC.19.5.813 PubMedWeb of Science®Google Scholar 68 Guiot HFL, van der Meer Jos WM, van Furth R. Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria. J Infect Dis 1981; 143: 644–654. 10.1093/infdis/143.5.644 CASPubMedWeb of Science®Google Scholar 69 Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlet JG, et al. Norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987; 106: 1–7. 10.7326/0003-4819-106-1-1 CASPubMedWeb of Science®Google Scholar 70 Rimola A, Bory F, Teres J, Perez-Ayuso RM, Arroyo V, Rodés J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5: 463–467. 10.1002/hep.1840050320 PubMedWeb of Science®Google Scholar 71 Watanabe T. Infectious drug resistance in enteric bacteria. N Engl J Med 1966; 275: 888–894. 10.1056/NEJM196610202751607 CASPubMedWeb of Science®Google Scholar 72 Breen KJ, Bryant RE, Levinson JD, Schenker S. Neomycin absorption in man. Ann Intern Med 1972; 76: 211–218. 10.7326/0003-4819-76-2-211 CASPubMedWeb of Science®Google Scholar 73 Wofson JS, Hooper DC. Norfloxacin: a new targeted flouroquinolone antimicrobial agent. Ann Intern Med 1988; 108: 238–251. 10.7326/0003-4819-108-2-238 PubMedWeb of Science®Google Scholar 74 de Vries-Hospers HG, Welling GW, van der Waaij D. Norfloxacin for selective decontamination: a study in human volunteers. Prog Clin Biol Res 1985; 181: 259–262. CASPubMedGoogle Scholar 75 King A, Warren C, Shannon K, Phillips I. In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother 1982; 21: 604–607. 10.1128/AAC.21.4.604 CASPubMedWeb of Science®Google Scholar 76 Edlund C, Bergan T, Josefsson K, Solberg R, Nord CE. Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. Scand J Infect Dis 1987; 19: 113–121. 10.3109/00365548709032386 CASPubMedWeb of Science®Google Scholar 77 Pecquet S, Andremont A, Tancrède C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob Agents Chemother 1986; 29: 1047–1052. 10.1128/AAC.29.6.1047 CASPubMedWeb of Science®Google Scholar 78 Sabbaj J, Sutter VL, Finegold SM. Ammonia production by fecal bacteria in hepatic coma [Abstract]. Clin Res 1971; 19: 176. Google Scholar 79 Ariza J, Gudiol F, Dolz C, Xiol J, Linares J, Bosch J, Pallares R. Evaluation of aztreonam in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatology 1986; 6: 906–910. 10.1002/hep.1840060516 PubMedWeb of Science®Google Scholar 80 Galy J, Mantel O. Concentrations of cefotaxime in human tissues and fluids: a review of published data. Nouv Presse Med 1981; 10: 565–573. CASPubMedWeb of Science®Google Scholar 81 Moreau L, Durand H, Biclet P. Cefotaxime concentrations in ascites. J Antimicrob Chemother 1980; 6: 121–122. 10.1093/jac/6.suppl_A.121 PubMedWeb of Science®Google Scholar 82 McNamara PJ, Trueb V, Stoeckel K. Protein binding of ceftriaxone in extravascular fluids. J Pharm Sci 1988; 77: 401–404. 10.1002/jps.2600770509 CASPubMedWeb of Science®Google Scholar 83 Van Gossum A, Quenon M, Van Gossum M, Herchuelz A, Thys JP. Penetration of cefoperazone into ascites. Euro J Clin Pharm 1989; 37: 577–580. 10.1007/BF00562548 CASPubMedWeb of Science®Google Scholar 84 Cardey J, Bouquet S, Breux JP, Becq-Giraudon B, Fourtillan JP, Beauchant M. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. Eur J Clin Pharmacol 1987; 33: 469–472. 10.1007/BF00544237 CASPubMedWeb of Science®Google Scholar 85 Silvian C, Bouquet S, Breux JP, Becq-Giraudon B, Beauchant M. Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis. Eur J Clin Pharm 1989; 37: 261–265. 10.1007/BF00679781 Web of Science®Google Scholar 86 Mercader J, Gomez J, Ruiz J, Garre MC, Valdes M. Use of cefriaxone in the treatment of bacterial infections in cirrhotic patients. Chemotherapy 1989; 35: 23–26. 10.1159/000238735 PubMedWeb of Science®Google Scholar 87 Fong T-L, Evangelos AA, Runyon BA, Reynolds TB. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989; 9: 423–426. 10.1002/hep.1840090313 CASPubMedWeb of Science®Google Scholar Citing Literature Volume12, Issue4October 1990Pages 776-781 ReferencesRelatedInformation
Referência(s)